244 related articles for article (PubMed ID: 21992603)
21. No evidence for functional selectivity of proxyfan at the human histamine H3 receptor coupled to defined Gi/Go protein heterotrimers.
Schnell D; Burleigh K; Trick J; Seifert R
J Pharmacol Exp Ther; 2010 Mar; 332(3):996-1005. PubMed ID: 19959746
[TBL] [Abstract][Full Text] [Related]
22. Covalent Inhibition of the Histamine H
Wágner G; Mocking TAM; Kooistra AJ; Slynko I; Ábrányi-Balogh P; Keserű GM; Wijtmans M; Vischer HF; de Esch IJP; Leurs R
Molecules; 2019 Dec; 24(24):. PubMed ID: 31835873
[TBL] [Abstract][Full Text] [Related]
23. Progress in the development of histamine H
Łażewska D; Kieć-Kononowicz K
Expert Opin Ther Pat; 2018 Mar; 28(3):175-196. PubMed ID: 29334795
[TBL] [Abstract][Full Text] [Related]
24. First metal-containing histamine H3 receptor ligands.
Sander K; Kottke T; Hoffend C; Walter M; Weizel L; Camelin JC; Ligneau X; Schneider EH; Seifert R; Schwartz JC; Stark H
Org Lett; 2010 Jun; 12(11):2578-81. PubMed ID: 20446742
[TBL] [Abstract][Full Text] [Related]
25. The evolution of histamine H₃ antagonists/inverse agonists.
Lebois EP; Jones CK; Lindsley CW
Curr Top Med Chem; 2011; 11(6):648-60. PubMed ID: 21261594
[TBL] [Abstract][Full Text] [Related]
26. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders.
Passani MB; Lin JS; Hancock A; Crochet S; Blandina P
Trends Pharmacol Sci; 2004 Dec; 25(12):618-25. PubMed ID: 15530639
[TBL] [Abstract][Full Text] [Related]
27. Novel histamine H(3)-receptor antagonists and partial agonists with a non-aminergic structure.
Nickel T; Bauer U; Schlicker E; Kathmann M; Göthert M; Sasse A; Stark H; Schunack W
Br J Pharmacol; 2001 Apr; 132(8):1665-72. PubMed ID: 11309237
[TBL] [Abstract][Full Text] [Related]
28. [Possible roles of brain histamine H3 receptors and the pharmacology of its ligands].
Onodera K; Watanabe T
Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Apr; 15(2):87-102. PubMed ID: 7796325
[TBL] [Abstract][Full Text] [Related]
29. Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.
Hancock AA; Diehl MS; Fey TA; Bush EN; Faghih R; Miller TR; Krueger KM; Pratt JK; Cowart MD; Dickinson RW; Shapiro R; Knourek-Segel VE; Droz BA; McDowell CA; Krishna G; Brune ME; Esbenshade TA; Jacobson PB
Inflamm Res; 2005 Apr; 54 Suppl 1():S27-9. PubMed ID: 15928821
[No Abstract] [Full Text] [Related]
30. Histamine H3 and H4 receptors as novel drug targets.
Tiligada E; Zampeli E; Sander K; Stark H
Expert Opin Investig Drugs; 2009 Oct; 18(10):1519-31. PubMed ID: 19758107
[TBL] [Abstract][Full Text] [Related]
31. Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo.
Gbahou F; Davenas E; Morisset S; Arrang JM
J Pharmacol Exp Ther; 2010 Sep; 334(3):945-54. PubMed ID: 20530654
[TBL] [Abstract][Full Text] [Related]
32. Benzylpiperidine variations on histamine H3 receptor ligands for improved drug-likeness.
Wingen K; Schwed JS; Isensee K; Weizel L; Zivković A; Odadzic D; Stark H
Bioorg Med Chem Lett; 2014 May; 24(10):2236-9. PubMed ID: 24745967
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
[TBL] [Abstract][Full Text] [Related]
34. Preclinical evaluation of the abuse potential of Pitolisant, a histamine H₃ receptor inverse agonist/antagonist compared with Modafinil.
Uguen M; Perrin D; Belliard S; Ligneau X; Beardsley PM; Lecomte JM; Schwartz JC
Br J Pharmacol; 2013 Jun; 169(3):632-44. PubMed ID: 23472741
[TBL] [Abstract][Full Text] [Related]
35. The histamine H3 receptor: from discovery to clinical trials with pitolisant.
Schwartz JC
Br J Pharmacol; 2011 Jun; 163(4):713-21. PubMed ID: 21615387
[TBL] [Abstract][Full Text] [Related]
36. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
[TBL] [Abstract][Full Text] [Related]
37. Design and evaluation of novel biphenyl sulfonamide derivatives with potent histamine H(3) receptor inverse agonist activity.
Covel JA; Santora VJ; Smith JM; Hayashi R; Gallardo C; Weinhouse MI; Ibarra JB; Schultz JA; Park DM; Estrada SA; Hofilena BJ; Pulley MD; Smith BM; Ren A; Suarez M; Frazer J; Edwards J; Hauser EK; Lorea J; Semple G; Grottick AJ
J Med Chem; 2009 Sep; 52(18):5603-11. PubMed ID: 19722526
[TBL] [Abstract][Full Text] [Related]
38. Keynote review: histamine H3 receptor antagonists reach out for the clinic.
Celanire S; Wijtmans M; Talaga P; Leurs R; de Esch IJ
Drug Discov Today; 2005 Dec; 10(23-24):1613-27. PubMed ID: 16376822
[TBL] [Abstract][Full Text] [Related]
39. Antihistaminergics and inverse agonism: potential therapeutic applications.
Monczor F; Fernandez N; Fitzsimons CP; Shayo C; Davio C
Eur J Pharmacol; 2013 Sep; 715(1-3):26-32. PubMed ID: 23831018
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.
Nagase T; Mizutani T; Ishikawa S; Sekino E; Sasaki T; Fujimura T; Ito S; Mitobe Y; Miyamoto Y; Yoshimoto R; Tanaka T; Ishihara A; Takenaga N; Tokita S; Fukami T; Sato N
J Med Chem; 2008 Aug; 51(15):4780-9. PubMed ID: 18598020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
